Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(5 years from now) | |
US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(5 years from now) | |
US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) |
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
8
United States
4
European Union
3
Denmark
3
Spain
2
Japan
2
Hong Kong
2
Germany
2
China
1
Australia
1
Korea, Republic of
1
Canada
1
Uruguay
1
Chile
1
Portugal
1
Russia
1
Poland
1
Slovenia
1
Mexico
1
Argentina
1
Brazil
1
South Africa
1
Hungary
1
Taiwan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8388941 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8323630 | NOVARTIS | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8268299 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(6 years from now) |
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
9
United States
4
Japan
2
Australia
2
Korea, Republic of
2
Canada
2
Spain
2
Poland
2
Hong Kong
2
Mexico
2
Brazil
2
China
2
South Africa
2
European Union
1
Denmark
1
Uruguay
1
Austria
1
Chile
1
Cyprus
1
Portugal
1
Russia
1
Slovenia
1
Argentina
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic